

# Total Synthesis of Fully Acetylated *N*-Acetylneuraminic Acid (Neu5Ac), 2-Deoxy- $\beta$ -Neu5Ac, and 4-*epi*-2-Deoxy- $\beta$ -Neu5Ac from D-glucose


Lian-Sheng Li, Yu-Lin Wu,\* and Yikang Wu

State Key Laboratory of Bio-organic and Natural Products Chemistry,  
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences,  
354 Fenglin Road, Shanghai 200032, China

ylwu@pub.sioc.ac.cn

Received January 12, 2000


## ABSTRACT



Sialic acid and its analogues have been synthesized using a salenCo(II) complex catalyzed hetero Diels–Alder reaction and oxidative azidation (CAN/NaN<sub>3</sub>) of silyl enol ether as the key steps.

Sialic acids (especially *N*-acetylneuraminic acid, Neu5Ac **1**) frequently occur at the terminal end of glycoconjugates, such as glycoproteins, glycolipids, and oligosaccharides, in cell membranes and nerve tissues of various living organisms.<sup>1</sup> They play a vital role<sup>2</sup> in numerous biological processes including cell-to-cell recognition, cell-adhesion, and tumor metastasis. Among the analogues of **1**, *N*-acetyl-2-deoxyneuraminic acid (**2**) and its 4-epimer are of particular interest, because they are inhibitors of Neu5Ac-associated enzymes such as *Vibrio cholerae* sialidase<sup>3</sup> and influenza viral neuraminidase.<sup>4</sup> Considerable attention has therefore been paid to developing effective methods for synthesis of both Neu5Ac (**1**)<sup>5,6</sup> and its 2-deoxy-2-H derivative (**2**).<sup>3,6d,7</sup> Herein we wish to report an efficient approach to *N*-acetylneuraminic acid


(Neu5Ac), 2-deoxy- $\beta$ -Neu5Ac, and 4-*epi*-2-deoxy- $\beta$ -Neu5Ac from D-glucose based on salenCo(II) (**3**) complex<sup>8</sup> catalyzed hetero Diels–Alder reactions.



The desired silyloxy diene **8** was prepared from the readily available D-glucose as shown in Scheme 1. Thus, 2,4-*O*-ethylidene-D-erythrose (**5**) was obtained using the established procedures.<sup>9</sup> Wittig reaction of **5** with Ph<sub>3</sub>P=CHCOCH<sub>3</sub> afforded unsaturated ketone **6**, which was then protected as

- (1) Gottschalk, A. *Nature* **1951**, 167, 845.
- (2) von Itzstein, M.; Thompson, R. J. *Top. Curr. Chem.* **1997**, 186, 119–170 and references therein.
- (3) Wallimann, K.; Vasella, A. *Helv. Chim. Acta* **1991**, 74, 1520–1532.
- (4) Flashner, M.; Kessler, J.; Tanenbaum, St. W. *Arch. Biochem. Biophys.* **1983**, 221, 188.
- (5) For reviews, see: (a) Tuppy, H.; Gottschalk, A. The Structure of sialic acids and their quantitation. In *Glycoproteins. Their composition, structure and function*; Gottschalk, A., Ed.; Elsevier: Amsterdam, 1972; p 403. (b) DeNinno, M. P. *Synthesis* **1991**, 583–593. For recently reported chemical synthesis of Neu5Ac and related compounds, see: (c) Banwell, M.; Savi, C. D.; Watson, K. J. *J. Chem. Soc., Perkin Trans. 1* **1998**, 2251–2252. (d) Takahashi, T.; Tsukamoto, H.; Kurosaki, M.; Yamada, H. *Synlett*

- 1997**, 1065–1066. (e) Chan, T.-H.; Lee, M.-C. *J. Org. Chem.* **1995**, 60, 4228–4232. (f) Gordon, D. M.; Whitesides, G. M. *J. Org. Chem.* **1993**, 58, 7937–7938. (g) Yamamoto, T.; Teshima, T.; Inami, K.; Shiba, T. *Tetrahedron Lett.* **1992**, 33, 325–328. (h) Csuk, R.; Hugener, M.; Vasella, A. *Helv. Chim. Acta* **1988**, 71, 609. (i) Danishefsky, S. J.; DeNinno, M. P.; Chen, S.-H. *J. Am. Chem. Soc.* **1988**, 110, 3929–3940. (j) Julina, R.; Müller, I.; Vasella, A.; Wyler, R. *Carbohydr. Res.* **1987**, 164, 415. (k) Baumberger, F.; Vasella, A. *Helv. Chim. Acta* **1986**, 69, 1205–1215. (l) Danishefsky, S. J.; DeNinno, M. P. *J. Org. Chem.* **1986**, 2615–2617.


Scheme 1<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) Paraldehyde, cat. H<sub>2</sub>SO<sub>4</sub>, 43%; (b) NaIO<sub>4</sub>, NaHCO<sub>3</sub>, H<sub>2</sub>O; (c) Ph<sub>3</sub>P=CHCOCH<sub>3</sub>, toluene, 90 °C, 66% over two steps; (d) methylal, cat. P<sub>2</sub>O<sub>5</sub>, CHCl<sub>3</sub>, 0 °C → room temperature, 88%; (e) TBSOTf, Et<sub>3</sub>N, 0 °C, 99%; (f) ethyl glyoxylate, **3** (10% mol), CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 62%.


MOM ether **7** (88% yield). Treatment of compound **7** with triflate and triethylamine at 0 °C for 30 min provided the corresponding diene **8** in 99% yield. The hetero Diels–Alder

reaction between compound **8** and ethyl glyoxylate (freshly distilled) catalyzed by (*S,S*)-salenCo(II) complex (**3**) (10% mol) at room temperature afforded cycloaddition product **9** in 62% isolated yield, along with a small amount of an isomer (<5% yield) and the byproducts<sup>10</sup> from the Mukaiyama reaction.

The next key step of our synthesis was to introduce an amine group at the C-5. We first tried to prepare  $\alpha$ -hydroxy ketone **10** by an AD reaction<sup>11</sup> of **9** under conditions similar to those used previously<sup>8d</sup> (Scheme 2). **10** was then transformed in parallel into mesylate **11**, tosylate **12**, or triflate **13** and treated separately with NaN<sub>3</sub>. To our surprise, the anticipated S<sub>N</sub>2 reaction leading to **17** did not occur. Instead, all runs gave predominantly the elimination product, presumably due to the steric crowding caused<sup>12</sup> by the larger substituent at C-6. We then tested the Mitsunobu reaction<sup>13</sup> (using DEAD, DPPA, Ph<sub>3</sub>P); the reaction was very complicated. The Sharpless asymmetric aminohydroxylation reaction<sup>14</sup> [LiOH/AcNHBr/K<sub>2</sub>Os(OH)<sub>4</sub>O<sub>2</sub> in *t*-BuOH/H<sub>2</sub>O] of **9** did not afford any **15** either. The Evans' copper-mediated aziridination reaction<sup>15</sup> gave the expected  $\alpha$ -amino ketone adduct **14** in 39% isolated yield, when **9** was treated with 10 mol % of CuClO<sub>4</sub><sup>16</sup> or Cu(OTf)<sub>2</sub> and 1.5 equiv (with respect to **9**) of PhI=NTs<sup>17</sup> in anhydrous MeCN at –30 °C.

Scheme 2<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) K<sub>2</sub>O<sub>2</sub>(OH)<sub>4</sub> (5% mol), (DHQD)<sub>2</sub>-PHAL (5% mol), NaHCO<sub>3</sub> (3 equiv), K<sub>2</sub>CO<sub>3</sub> (3 equiv), K<sub>3</sub>Fe(CN)<sub>6</sub> (3 equiv), *t*-BuOH/H<sub>2</sub>O (1:1), 0 °C, 78%; (b) NaN<sub>3</sub> (3 equiv), CAN (2.5 equiv), CH<sub>3</sub>CN, –25 °C, 61%; (c) PhI=NTs (1 equiv), Cu(CH<sub>3</sub>CN)<sub>4</sub>ClO<sub>4</sub> (10% mol), CH<sub>3</sub>CN, –20 → –10 °C, 39%; (d) Na/NH<sub>3</sub>, or Na/naphthalene, THF, –78 °C, ≤ 10%; (e) CH<sub>3</sub>COSH, room temperature, 90%; (f) NaBH<sub>4</sub>, EtOH, –30 °C, 85%; (g) *p*-TsOH (2 equiv), EtOH, reflux, then Ac<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 96%; (h) LiAl[O(CH<sub>3</sub>)<sub>3</sub>]<sub>3</sub>H, THF, –10 °C, 80%; (i) MOMCl, *i*-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 91%; (j) H<sub>2</sub>, Pd/C (10%), room temperature, then Ac<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 95%; (k) same as (g), 92%.

Scheme 3<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) NaBH<sub>4</sub>, EtOH, -30 °C, 83%; (b) MOMCl, *i*-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → room temperature, 90% (c) LDA, MoOPH, THF, -78 °C, 50%; (d) Ac<sub>2</sub>O, Py, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 84%; (e) H<sub>2</sub>, Pd/C (10%), EtOH, 30 °C, then Ac<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 68%; (f) *p*-TsOH, EtOH, reflux, then Ac<sub>2</sub>O, Py, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 73%.

However, the following removal of the tosyl group in **14** using either Na/NH<sub>3</sub> or Na/naphthalene suffered from very low yield (<10%), although the expected product **15** did form. This difficulty made us reconsider introducing an azide group at C-5 first.

Oxidative azidation (CAN/NaN<sub>3</sub>) of silyl enol ether is also an established means to prepare  $\alpha$ -azido ketone. Although there are reports<sup>18,19</sup> on the ineffectiveness of this reaction, we found that the yield could be significantly improved by modifying the procedure. Thus, treatment of **9** with NaN<sub>3</sub> (3.0 equiv) in anhydrous CH<sub>3</sub>CN at -25 °C followed by slow addition of CAN (2.5 equiv in CH<sub>3</sub>CN) led to the desired product **17** in a 61% isolated yield, together with a small amount of **18** (10%). It is noteworthy that unlike all the previously reported procedures, the present one can be run easily on larger scales (1.5–2.5 g) without lowering the yield.

Conversion of **17** to the corresponding acetamide **15** using a modification of Rosen's method<sup>20</sup> (Scheme 2) was realized

in 90% yield. Reduction of the ketone of **15** with NaBH<sub>4</sub> at -30 °C afforded the desired *anti* product **19** in 85% yield. All the protecting groups in compound **19** were then removed by treatment with *p*-TsOH in refluxing EtOH. Acetylation of the unmasked hydroxyl groups to afford the corresponding acetate **20**<sup>21</sup> was fulfilled (96%) using acetic anhydride in the presence of Et<sub>3</sub>N and a catalytic amount of DMAP.

The 4-*epi* analogue **24** was also prepared according to Scheme 2. Reduction of the ketone carbonyl in **17** with the bulky reducing reagent LiAl[O(CH<sub>3</sub>)<sub>3</sub>]<sub>3</sub>H<sup>22</sup> at -10 °C gave *syn* product **21** in 80% isolated yield. After protection of the C-4 hydroxyl as the MOM ether (**22**, 91% yield), the azido functionality was hydrogenated to give an amine, which was converted to **23** in high yield (95%). Then, under the same conditions, compound **23** was transformed into **24**, the fully acetylated 4-*epi*-2-deoxy- $\beta$ -Neu5Ac, in 92% yield.<sup>23</sup>

The total synthesis of sialic acid from intermediate **17** require oxidation at C-2. Thus, reduction of the ketone,

(6) Enzyme synthesis of Neu5Ac and related compounds: (a) Bednarski, M. D.; Chenault, H. K.; Simon, E. S.; Whitesides, G. M. *J. Am. Chem. Soc.* **1987**, *109*, 1283–1285. (b) Auge, C.; David, S.; Gautheron, C. *Tetrahedron Lett.* **1984**, *25*, 4663–4664. (c) Auge, C.; David, S.; Gautheron, C.; Veyrières, A. *Tetrahedron Lett.* **1985**, *26*, 2439–2440. (d) Kim, M.-J.; Hennen, W. J.; Sweers, H. M.; Wong, C.-H. *J. Am. Chem. Soc.* **1988**, *110*, 6481–6486. (e) Wong, C.-H.; Whitesides, G. M. *Enzymes in Synthetic Organic Chemistry*, Tetrahedron Organic Chemistry Series Volume 12; Pergamon: Oxford, 1994. (f) Sugai, T.; Kuboki, A.; Hiramatsu, S.; Okazaki, H.; Ohta, H. *Bull. Chem. Soc. Jpn.* **1995**, *68*, 3581.

(7) Chemical synthesis of 2-deoxy-2H derivatives of Neu5Ac: (a) Gervay, J.; Gregar, T. *Tetrahedron Lett.* **1997**, *38*, 5921–5924. (b) Bandgar, B. P.; Zbiral, E. *Carbohydr. Res.* **1995**, *270*, 201–210. (c) Wallimann, K.; Vasella, A. *Helv. Chim. Acta* **1990**, *73*, 1359–1372. (d) Bandgar, B. P.; Hartmann, M.; Schmid, W.; Zbiral, E. *Liebigs Ann. Chem.* **1990**, 1185–1195. (e) Schmid, W.; Christian, R.; Zbiral, E. *Tetrahedron Lett.* **1988**, *29*, 3643–3646.

(8) (a) Hu, Y.-J.; Huang, X.-D.; Yao, Z.-J.; Wu, Y.-L. *J. Org. Chem.* **1998**, *63*, 2456–2461. (b) Li, L.-Sh.; Wu, Y.-K.; Hu, Y.-J.; Wu, Y.-L. *Tetrahedron: Asymmetry* **1998**, *9*, 2271–2277. (c) Hu, Y.-J.; Huang, X.-D.; Wu, Y.-L. *J. Carbohydr. Chem.* **1998**, *17*, 1095. (d) Li, L.-Sh.; Wu, Y.-K.; Wu, Y.-L. *J. Carbohydr. Chem.* **1999**, *18*, 1067–1077.

(9) Barker, R.; MacDonnald, D. L. *J. Am. Chem. Soc.* **1960**, *82*, 2301–2303.

(10) For discussion about the mechanism of related reactions catalyzed by other salen metal complex catalysts, see: Schaus, S. E.; Brnalt, J.; Jacobsen, E. N. *J. Org. Chem.* **1998**, *63*, 403.

(11) (a) Hashiyama, T.; Morikawa, K.; Sharpless, K. B. *J. Org. Chem.* **1992**, *57*, 5067–5068. (b) Morikawa, K.; Park, J.; Andersson, P. G.; Hashiyama, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1993**, *115*, 8463–8064.

(12) Neufellner, E.; Kapeller, H.; Griengl, H. *Tetrahedron* **1998**, *54*, 11043–11062.

(13) Mitsunobu, O. *Synthesis* **1981**, 1–28.

(14) (a) Phukan, P.; Sudalai, A. *Tetrahedron: Asymmetry* **1998**, *9*, 1001–1005. (b) Bruncko, M.; Schlingloff, G.; Sharpless, K. B. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 1483–1486.

(15) Evans, D. A.; Faul, M. M.; Bilodeau, M. T. *J. Am. Chem. Soc.* **1994**, *116*, 2742–2753.

(16) The catalyst was prepared from Cu<sub>2</sub>O according to the reported procedure: Kubas, G. J. *Inorg. Synth.* **1979**, *19*, 90–92.

(17) The I–N ylide was prepared by following the reported procedure: Yamada, Y.; Yamamoto, T.; Okawara, M. *Chem. Lett.* **1975**, 361–362.

(18) Auberson, Y.; Vogel, P. *Tetrahedron* **1990**, *46*, 7019–7032.

(19) Magnus, P.; Barth, L. *Tetrahedron Lett.* **1992**, *33*, 2777–2780.

(20) Rosen, T.; Lico, I. M.; Chu, D. T. W. *J. Org. Chem.* **1988**, *53*, 1580–1582.

(21) NMR data for compound **20**: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.59 (1H, d, *J* = 8.5 Hz, NH), 5.42 (1H, ddd, *J* = 7.1, 5.1, 1.2 Hz), 5.25 (1H, dd, *J* = 4.7, 1.6 Hz), 5.11 (1H, ddd, *J* = 5.1, dt, *J* = 11.5, 4.9 Hz), 4.60 (1H, dd, *J* = 12.1, 2.2 Hz), 4.29 (1H, dd, *J* = 12.3, 6.9 Hz), 4.22 (2H, dq, *J* = 7.1, 1.3 Hz), 4.05 (1H, dd, *J* = 12.1, 2.2 Hz), 3.95 (1H, q, *J* = 10.2 Hz), 3.67 (1H, *J* = 10.6, 1.4 Hz), 2.39 (1H, ddd, *J* = 12.6, 4.9, 2.2 Hz), 2.11, 2.10, 2.06, 2.05, 1.98 (15H, 5s), 1.76 (1H, q, *J* = 12.1 Hz), 1.28 (3H, t, *J* = 7.1 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  170.81, 170.64, 170.31, 170.25, 170.08, 168.71, 78.70, 74.12, 71.40, 70.82, 69.85, 62.73, 61.50, 51.84, 33.78, 23.24, 21.01, 20.94, 20.91, 20.72, 14.00; EIMS (*m/z*) 490 (*M*<sup>+</sup> + 1); [ $\alpha$ ]<sub>D</sub> = 34.2 (*c* 0.25, CHCl<sub>3</sub>).

(22) Boireau, G.; Deberly, A.; Toneva, R. *Synlett* **1993**, 585–587.

(23) NMR data for compound **24**: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.82 (1H, d, *J* = 9.0 Hz, NH), 5.43 (1H, dt, *J* = 9.0, 2.4 Hz), 5.26 (1H, dd, *J* = 6.6, 3.0 Hz), 5.10 (1H, m), 4.47 (1H, dd, *J* = 12.6, 2.4 Hz), 4.43 (1H, dd, *J* = 6.6, 2.4 Hz), 4.28–4.22 (3H, m), 4.12 (1H, t, *J* = 7.2 Hz), 4.14–4.11 (1H, m), 2.52 (1H, ddd, *J* = 15.0, 4.2, 2.4 Hz), 2.17, 2.12, 2.05, 2.04, 2.01 (15H, 5s), 2.09 (1H, ddd, *J* = 15.0, 7.2, 3.0 Hz), 1.26 (3H, t, *J* = 7.1 Hz); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  171.08, 171.05, 170.62, 170.38, 170.23, 169.42, 70.83, 70.65, 69.37, 68.78, 62.38, 61.19, 60.35, 47.24, 30.08, 23.19, 20.96, 20.91, 20.75, 20.69, 13.69; EIMS (*m/z*) 490 (*M*<sup>+</sup> + 1); [ $\alpha$ ]<sub>D</sub> = 98.6 (*c* 1.09, CHCl<sub>3</sub>).

following protection of the resulting hydroxy, furnished the desired *anti*-azido MOM ether **26** (Scheme 3). Oxidation of the lithium enolate of **26** with MoO<sub>5</sub>·Py·HMPA (MoOPH)<sup>24</sup> gave the 2- $\alpha$ -OH product (along with traces of the 2- $\beta$ -OH isomer) in 50% isolated yield (70%, based on recovered **26**). Acetylation of the hydroxyl at C-2 afforded compound **28** (84%). Then following a procedure similar to that described above, **28** was transformed into pentaacetylated ethyl ester

---

(24) Recently, Burke reported that the total synthesis of KDO from 2-deoxy-KDO used MoOPH as the oxidant: Burke, S. D.; Sametz, G. M. *Org. Lett.* **1999**, *1*, 71–74. The MoOPH was prepared according to the reported procedure: Vedejs, E.; Larsen, S. *Org. Synth.* **1986**, *64*, 127–137.

(25) NMR data of compound **30**: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.61 (1H, d, *J* = 9.3 Hz, NH), 5.49 (1H, ddd, *J* = 10.4, 5.8, 3.6 Hz), 5.26 (1H, dd, *J* = 5.0, 1.6 Hz), 5.22–5.18 (1H, m), 4.63 (1H, dd, *J* = 12.4, 2.5 Hz), 4.29 (1H, dd, *J* = 9.0, 7.9 Hz), 4.23 (2H, q, *J* = 7.1 Hz), 4.12 (1H, q, *J* = 10.2 Hz), 3.75 (1H, dd, *J* = 10.9, 1.9 Hz), 2.36 (1H, dd, *J* = 13.5, 4.9 Hz), 1.85 (1H, dd, *J* = 13.5, 11.2 Hz), 2.09, 2.08, 2.05, 2.04, 2.03, 1.98 (18H, 6s), 1.29 (3H, t, *J* = 7.1 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  171.08, 170.75, 170.29  $\times$  2, 170.03, 169.76, 167.29, 98.31, 73.19, 71.25, 69.65, 68.79, 62.83, 61.96, 51.34, 37.53, 23.20, 20.98, 20.91, 20.79, 20.74, 14.00; [ $\alpha$ ]<sub>D</sub> = 40.4 (*c* 0.52, CHCl<sub>3</sub>).

**30**.<sup>25</sup> The physical data of our synthetic sample are identical to those reported<sup>5f</sup> by Whitesides.

In summary, we have established an effective synthesis of both sialic acid and its analogues. Further studies on the total synthesis of Neu2en5Ac and Zanamivir<sup>26</sup> (GG167) are currently ongoing in this laboratory, and the results will be reported in due time.

**Acknowledgment.** We thank the Chinese Academy of Sciences (KJ-952-S1-503, KJ-95-A1-504), the Chinese Natural Science Foundation (29790126, 29872049), and the State Ministry of Science and Technology of China (970211006-6) for financial support.

OL0055418

---

(26) (a) von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. *Nature* **1993**, *363*, 418–423. (b) Hayden, F. G.; Treanor, J. J.; Betts, R. F.; Lobo, M.; Esinhart, J.; Hussey, E. *J. Am. Med. Assoc.* **1996**, *275*, 295.